Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Other Non-Current Assets

Last Annual Value

183.11K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Other Non-Current Assets

ANEB · NASDAQ
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
183.11K
N/AN/AN/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
0.00
N/AN/AN/A
114.05K
9.3%N/AN/A
6.74M
-0.4%-0.9%N/A
1.31M
-28.7%52.6%14.7%
0.00
N/AN/AN/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
-176.77K
N/AN/AN/A
337.00K
-58.5%-41.3%N/A
2.52M
320.1%-36.8%66.9%
9.51M
3.9%117.8%N/A
207.00K
-29.1%-20.5%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72